Probiotics are foods or products that contain live microorganisms that benefit the host when administered. In this clinical review, we evaluate the literature associated with using probiotics in common pediatric gastrointestinal disorders, focusing specifically on antibiotic-associated diarrhea, acute gastroenteritis, Clostridium difficile infection (CDI), colic, inflammatory bowel disease, and functional gastrointestinal diseases. Meta-analysis of several randomized controlled trials have confirmed benefit for the administration of Lactobacillus rhamnosus GG and Saccharomyces boulardii to prevent antibiotic-associated diarrhea and to treat acute infectious diarrhea. Individual studies have also suggested benefit of probiotics to prevent acute gastroenteritis and serve as an adjunct in ulcerative colitis, pouchitis, antibiotic-associated diarrhea, CDI, functional abdominal pain, irritable bowel syndrome, and colic in breastfed babies. Although promising, larger well-designed studies need to confirm these findings. There is currently insufficient evidence to recommend probiotics for the treatment of constipation-predominant irritable bowel syndrome or Crohn’s disease.
De FilippoCCavalieriDDi PaolaM. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A. 2010;107(33):14691-14696.
2.
ScheppachWWeilerF. The butyrate story: old wine in new bottles?Curr Opin Clin Nutr Metab Care. 2004;7(5):563-567.
3.
LeyRETurnbaughPJKleinSGordonJI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444(7122):1022-1023.
4.
JohnsonCLVersalovicJ. The human microbiome and its potential importance to pediatrics. Pediatrics. 2012;129(5):950-960.
5.
WanLYMChenZJShahNPEl-NezamiH. Modulation of intestinal epithelial defense responses by probiotic bacteria [published online January 28, 2015]. Crit Rev Food Sci Nutr.
6.
IzadniaFWongCTKocoshisSA. Brewer’s yeast and Saccharomyces boulardii both attenuate Clostridium difficile–induced colonic secretion in the rat. Dig Dis Sci. 1998;43(9):2055-2060.
7.
CastagliuoloIRieglerMFValenickLLaMontJTPothoulakisC. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun. 1999;67(1):302-307.
8.
AndersonRCCooksonALMcNabbWC. Lactobacillus plantarum MB452 enhances the function of the intestinal barrier by increasing the expression levels of genes involved in tight junction formation. BMC Microbiol. 2010;10:316.
9.
CharbonneauDGibbRDQuigleyEMM. Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. Gut Microbes. 2013;4(3):201-211.
10.
RougéCPiloquetHButelM-J. Oral supplementation with probiotics in very-low-birth-weight preterm infants: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr. 2009;89(6):1828-1835.
11.
MorelliL. Yogurt, living cultures, and gut health. Am J Clin Nutr. 2014;99(5):1248S-1250S.
12.
PochartPDewitODesjeuxJFBourliouxP. Viable starter culture, beta-galactosidase activity, and lactose in duodenum after yogurt ingestion in lactase-deficient humans. Am J Clin Nutr. 1989;49(5):828-831.
13.
GuarnerFKhanAGGarischJ. World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011. J Clin Gastroenterol. 2012;46(6):468-481.
14.
Van OdijkJKullIBorresMP. Breastfeeding and allergic disease: a multidisciplinary review of the literature (1966-2001) on the mode of early feeding in infancy and its impact on later atopic manifestations. Allergy. 2003;58(9):833-843.
15.
HascoëtJ-MHubertCRochatF. Effect of formula composition on the development of infant gut microbiota. J Pediatr Gastroenterol Nutr. 2011;52(6):756-762.
16.
JohnstonBCGoldenbergJZVandvikPOSunXGuyattGH. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev Online. 2011;(11):CD004827.
Van den NieuwboerMBrummerRJGuarnerFMorelliLCabanaMClaassenE. Safety of probiotics and synbiotics in children under 18 years of age. Benef Microbes. March2015:1-16.
HennequinCKauffmann-LacroixCJobertA. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis. 2000;19(1):16-20.
21.
ThygesenJBGlerupHTarpB. Saccharomyces boulardii fungemia caused by treatment with a probioticum. BMJ Case Rep. 2012;2012. doi:10.1136/bcr.06.2011.4412.
22.
EgervärnMRoosSLindmarkH. Identification and characterization of antibiotic resistance genes in Lactobacillus reuteri and Lactobacillus plantarum. J Appl Microbiol. 2009;107(5):1658-1668.
23.
RosanderAConnollyERoosS. Removal of antibiotic resistance gene-carrying plasmids from Lactobacillus reuteri ATCC 55730 and characterization of the resulting daughter strain, L. reuteri DSM 17938. Appl Environ Microbiol. 2008;74(19):6032-6040.
24.
SavinoFPelleEPalumeriEOggeroRMinieroR. Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study. Pediatrics. 2007;119(1):e124-e130.
25.
SavinoFCordiscoLTarascoV. Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial. Pediatrics. 2010;126(3):e526-e533.
26.
SzajewskaHGyrczukEHorvathA. Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2013;162(2):257-262.
27.
SungVHiscockHTangMLK. Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomised trial. BMJ. 2014;348:g2107.
28.
ChauKLauEGreenbergS. Probiotics for infantile colic: a randomized, double-blind, placebo-controlled trial investigating Lactobacillus reuteri DSM 17938. J Pediatr. 2015;166(1):74-78.
29.
SavinoFCerattoSPoggiECartosioMECordero di MontezemoloLGiannattasioA. Preventive effects of oral probiotic on infantile colic: a prospective, randomised, blinded, controlled trial using Lactobacillus reuteri DSM 17938. Benef Microbes. December2014:1-7.
30.
IndrioFDi MauroARiezzoG. Prophylactic use of a probiotic in the prevention of colic, regurgitation, and functional constipation: a randomized clinical trial. JAMA Pediatr. 2014;168(3):228-233.
31.
WesselMACobbJCJacksonEBHarrisGSDetwilerAC. Paroxysmal fussing in infancy, sometimes called “colic.”Pediatrics. 1954;14(5):421-435.
32.
SaavedraJMAbi-HannaAMooreNYolkenRH. Long-term consumption of infant formulas containing live probiotic bacteria: tolerance and safety. Am J Clin Nutr. 2004;79(2):261-267.
33.
RosanderAConnollyERoosS. Removal of antibiotic resistance gene-carrying plasmids from Lactobacillus reuteri ATCC 55730 and characterization of the resulting daughter strain, L. reuteri DSM 17938. Appl Environ Microbiol. 2008;74(19):6032-6040.
34.
SaavedraMALda CostaJSDGarciasGHortaBLTomasiEMendonçaR. Infantile colic incidence and associated risk factors: a cohort study [in Portuguese]. J Pediatr (Rio J). 2003;79(2):115-122.
35.
TurckDBernetJ-PMarxJ. Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population. J Pediatr Gastroenterol Nutr. 2003;37(1):22-26.
36.
KotowskaMAlbrechtPSzajewskaH. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther. 2005;21(5):583-590.
37.
ArvolaTLaihoKTorkkeliS. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics. 1999;104(5):e64.
38.
RuszczyńskiMRadzikowskiASzajewskaH. Clinical trial: effectiveness of Lactobacillus rhamnosus (strains E/N, Oxy and Pen) in the prevention of antibiotic-associated diarrhoea in children. Aliment Pharmacol Ther. 2008;28(1):154-161.
39.
ShanL-SHouPWangZ-J. Prevention and treatment of diarrhoea with Saccharomyces boulardii in children with acute lower respiratory tract infections. Benef Microbes. 2013;4(4):329-334.
40.
SzajewskaHGuarinoAHojsakI. Use of probiotics for management of acute gastroenteritis: a position paper by the ESPGHAN Working Group for Probiotics and Prebiotics. J Pediatr Gastroenterol Nutr. 2014;58(4):531-539.
41.
GuarinoALo VecchioACananiRB. Probiotics as prevention and treatment for diarrhea. Curr Opin Gastroenterol. 2009;25(1):18-23.
42.
SzajewskaHSkórkaARuszczyńskiMGieruszczak-BiałekD. Meta-analysis: Lactobacillus GG for treating acute gastroenteritis in children—updated analysis of randomised controlled trials. Aliment Pharmacol Ther. 2013;38(5):467-476.
43.
SindhuKNCSowmyanarayananTVPaulA. Immune response and intestinal permeability in children with acute gastroenteritis treated with Lactobacillus rhamnosus GG: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2014;58(8):1107-1115.
44.
SzajewskaHSkórkaA. Saccharomyces boulardii for treating acute gastroenteritis in children: updated meta-analysis of randomized controlled trials. Aliment Pharmacol Ther. 2009;30(9):960-961.
45.
FeizizadehSSalehi-AbargoueiAAkbariV. Efficacy and safety of Saccharomyces boulardii for acute diarrhea. Pediatrics. 2014;134(1):e176-e191.
46.
CoconnierMHBernetMFChauvièreGServinAL. Adhering heat-killed human Lactobacillus acidophilus, strain LB, inhibits the process of pathogenicity of diarrhoeagenic bacteria in cultured human intestinal cells. J Diarrhoeal Dis Res. 1993;11(4):235-242.
47.
SzajewskaHRuszczyńskiMKolačekS. Meta-analysis shows limited evidence for using Lactobacillus acidophilus LB to treat acute gastroenteritis in children. Acta Paediatr. 2014;103(3):249-255.
48.
İşlekASayarEYılmazABaysanBÖMutluDArtanR. The role of Bifidobacterium lactis B94 plus inulin in the treatment of acute infectious diarrhea in children. Turk J Gastroenterol. 2014;25(6):628-633.
49.
MerensteinDGonzalezJYoungAGRobertsRFSandersMEPettersonS. Study to investigate the potential of probiotics in children attending school. Eur J Clin Nutr. 2011;65(4):447-453.
50.
HatakkaKSavilahtiEPönkäA. Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. BMJ. 2001;322(7298):1327.
51.
WeizmanZAsliGAlsheikhA. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics. 2005;115(1):5-9.
52.
RochetVRigottier-GoisLLevenezF. Modulation of Lactobacillus casei in ileal and fecal samples from healthy volunteers after consumption of a fermented milk containing Lactobacillus casei DN-114 001Rif. Can J Microbiol. 2008;54(8):660-667.
53.
MerensteinDMurphyMFokarA. Use of a fermented dairy probiotic drink containing Lactobacillus casei (DN-114 001) to decrease the rate of illness in kids: the DRINK study: a patient-oriented, double-blind, cluster-randomized, placebo-controlled, clinical trial. Eur J Clin Nutr. 2010;64(7):669-677.
54.
SurDMannaBNiyogiSK. Role of probiotic in preventing acute diarrhoea in children: a community-based, randomized, double-blind placebo-controlled field trial in an urban slum. Epidemiol Infect. 2011;139(6):919-926.
55.
SazawalSDhingraUHiremathG. Prebiotic and probiotic fortified milk in prevention of morbidities among children: community-based, randomized, double-blind, controlled trial. PLoS One. 2010;5(8):e12164.
56.
KellyCPPothoulakisCLaMontJT. Clostridium difficile colitis. N Engl J Med. 1994;330(4):257-262.
57.
LessaFCMuYBambergWM. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825-834.
58.
GoldenbergJZMaSSYSaxtonJD. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2013;5:CD006095.
59.
NaJYParkJMLeeKSKangJOOhSHKimYJ. Clinical characteristics of symptomatic Clostridium difficile infection in children: conditions as infection risks and whether probiotics is effective. Pediatr Gastroenterol Hepatol Nutr. 2014;17(4):232-238.
60.
McFarlandLVSurawiczCMGreenbergRN. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994;271(24):1913-1918.
61.
SurawiczCMMcFarlandLVGreenbergRN. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined withSaccharomyces boulardii. Clin Infect Dis. 2000;31(4):1012-1017.
62.
PothoulakisCKellyCPJoshiMA. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology. 1993;104(4):1108-1115.
63.
CastagliuoloIRieglerMFValenickLLaMontJTPothoulakisC. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun. 1999;67(1):302-307.
64.
BeausoleilMFortierNGuénetteS. Effect of a fermented milk combining Lactobacillus acidophilus Cl1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial. Can J Gastroenterol J Can Gastroenterol. 2007;21(11):732-736.
65.
GaoXWMubasherMFangCYReiferCMillerLE. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile–associated diarrhea prophylaxis in adult patients. Am J Gastroenterol. 2010;105(7):1636-1641.
66.
SampalisJPsaradellisERampakakisE. Efficacy of BIO K+ CL1285® in the reduction of antibiotic-associated diarrhea—a placebo controlled double-blind randomized, multi-center study. Arch Med Sci AMS. 2010;6(1):56-64.
67.
GoldsteinEJCJohnsonSMaziadeP-J. Pathway to prevention of nosocomial Clostridium difficile infection. Clin Infect Dis. 2015;60(suppl 2):S148-S158.
68.
OrelRKamhi TropT. Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease. World J Gastroenterol. 2014;20(33):11505-11524.
69.
BennetJDBrinkmanM. Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet. 1989;1(8630):164.
70.
RembackenBJSnellingAMHawkeyPMChalmersDMAxonAT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999;354(9179):635-639.
71.
OlivaSDi NardoGFerrariF. Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther. 2012;35(3):327-334.
72.
ZoccoMAdal VermeLZCremoniniF. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 2006;23(11):1567-1574.
73.
GuptaPAndrewHKirschnerBSGuandaliniS. Is Lactobacillus GG helpful in children with Crohn’s disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr. 2000;31(4):453-457.
74.
Van GossumADewitOLouisE. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn’s disease after lleo-caecal resection. Inflamm Bowel Dis. 2007;13(2):135-142.
75.
GuslandiMGiolloPTestoniPA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol. 2003;15(6):697-698.
76.
MieleEPascarellaFGiannettiEQuagliettaLBaldassanoRNStaianoA. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 2009;104(2):437-443.
77.
HuynhHQdeBruynJGuanL. Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2009;15(5):760-768.
78.
SoodAMidhaVMakhariaGK. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7(11):1202-1209, 1209.e1.
79.
TursiABrandimarteGPapaA. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2010;105(10):2218-2227.
80.
BibiloniRFedorakRNTannockGW. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol. 2005;100(7):1539-1546.
81.
IshikawaHAkedoIUmesakiYTanakaRImaokaAOtaniT. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr. 2003;22(1):56-63.
82.
KatoKMizunoSUmesakiY. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther. 2004;20(10):1133-1141.
83.
TsudaYYoshimatsuYAokiH. Clinical effectiveness of probiotics therapy (BIO-THREE) in patients with ulcerative colitis refractory to conventional therapy. Scand J Gastroenterol. 2007;42(11):1306-1311.
84.
CuiH-HChenC-LWangJ-D. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol. 2004;10(10):1521-1525.
85.
FurrieEMacfarlaneSKennedyA. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut. 2005;54(2):242-249.
86.
IshikawaHMatsumotoSOhashiY. Beneficial effects of probiotic bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: a randomized controlled study. Digestion. 2011;84(2):128-133.
87.
FujimoriSTatsuguchiAGudisK. High dose probiotic and prebiotic cotherapy for remission induction of active Crohn’s disease. J Gastroenterol Hepatol. 2007;22(8):1199-1204.
GionchettiPRizzelloFMorselliC. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum. 2007;50(12):2075-2084.
90.
GionchettiPRizzelloFHelwigU. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003;124(5):1202-1209.
91.
GionchettiPRizzelloFVenturiA. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119(2):305-309.
92.
MimuraTRizzelloFHelwigU. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53(1):108-114.
93.
KuismaJMentulaSJarvinenHKahriASaxelinMFarkkilaM. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther. 2003;17(4):509-515.
94.
SchultzMTimmerAHerfarthHHSartorRBVanderhoofJARathHC. Lactobacillus GG in inducing and maintaining remission of Crohn’s disease. BMC Gastroenterol. 2004;4:5.
95.
PranteraCScribanoMLFalascoGAndreoliALuziC. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: a randomised controlled trial with LactobacillusGG. Gut. 2002;51(3):405-409.
96.
BousvarosAGuandaliniSBaldassanoRN. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn’s disease. Inflamm Bowel Dis. 2005;11(9):833-839.
97.
MarteauPLémannMSeksikP. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled GETAID trial. Gut. 2006;55(6):842-847.
98.
SteedHMacfarlaneGTBlackettKL. Clinical trial: the microbiological and immunological effects of synbiotic consumption—a randomized double-blind placebo-controlled study in active Crohn’s disease. Aliment Pharmacol Ther. 2010;32(7):872-883.
99.
DrossmanDA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;130(5):1377-1390.
100.
ChichlowskiMRudolphC. Visceral pain and gastrointestinal microbiome. J Neurogastroenterol Motil. 2015;21(2):172-181.
101.
SaulnierDMRiehleKMistrettaT-A. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology. 2011;141(5):1782-1791.
102.
KorterinkJJOckeloenLBenningaMATabbersMMHilbinkMDeckers-KockenJM. Probiotics for childhood functional gastrointestinal disorders: a systematic review and meta-analysis. Acta Paediatr. 2014;103(4):365-372.
103.
HorvathADziechciarzPSzajewskaH. Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood. Aliment Pharmacol Ther. 2011;33(12):1302-1310.
104.
GuandaliniSMagazzùGChiaroA. VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr. 2010;51(1):24-30.
105.
BausermanMBaussermanMMichailS. The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr. 2005;147(2):197-201.
106.
FrancavillaRMinielloVMagistàAM. A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain [published online November 15, 2010]. Pediatrics.
107.
GawrońskaADziechciarzPHorvathASzajewskaH. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther. 2007;25(2):177-184.
108.
DimidiEChristodoulidesSFragkosKCScottSMWhelanK. The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2014;100(4):1075-1084.
109.
CoccorulloPStrisciuglioCMartinelliMMieleEGrecoLStaianoA. Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study. J Pediatr. 2010;157(4):598-602.
110.
BuL-NChangM-HNiY-HChenH-LChengC-C. Lactobacillus casei rhamnosus Lcr35 in children with chronic constipation. Pediatr Int. 2007;49(4):485-490.
111.
BanaszkiewiczASzajewskaH. Ineffectiveness of Lactobacillus GG as an adjunct to lactulose for the treatment of constipation in children: a double-blind, placebo-controlled randomized trial. J Pediatr. 2005;146(3):364-369.
112.
WallerPAGopalPKLeyerGJ. Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults. Scand J Gastroenterol. 2011;46(9):1057-1064.
113.
TabbersMMChmielewskaARoseboomMG. Fermented milk containing Bifidobacterium lactis DN-173 010 in childhood constipation: a randomized, double-blind, controlled trial. Pediatrics. 2011;127(6):e1392-e1399.
114.
VanderhoofJAWhitneyDBAntonsonDLHannerTLLupoJVYoungRJ. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J Pediatr. 1999;135(5):564-568.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
